Erin Ducharme1, Jeffrey M Weinberg. 1. St. Luke's-Roosevelt Hospital Center, Department of Dermatology, 1090 Amsterdam Avenue, Suite 11D, New York, NY 10025, USA.
Abstract
BACKGROUND: In some patients with psoriasis the inflammatory process fueling skin lesions also afflicts their joints in a condition called psoriatic arthritis. TNF-alpha has been shown to play a central role in the pathogenesis of both cutaneous and joint disease. Etanercept is a soluble fusion protein that binds TNF-alpha, rendering the molecule inactive and making etanercept an effective, targeted therapeutic option for many TNF-mediated inflammatory diseases. OBJECTIVE: To review the key clinical trials which evaluated efficacy of etanercept for the treatment of psoriasis and psoriatic arthritis, discuss various off-label uses for this therapeutic agent and describe the adverse events associated with its use. METHODS: A search of Medline for relevant articles on etanercept and psoriasis. RESULTS/ CONCLUSION: Etanercept has demonstrated efficacy in the treatment of skin and joint manifestations of psoriatic disease, thus gaining FDA approval for use in both. A growing number of off-label dermatological uses for etanercept have been proposed, with variable success reported in individual cases or small series. Since its introduction little over a decade ago, etanercept has maintained a favorable safety profile.
BACKGROUND: In some patients with psoriasis the inflammatory process fueling skin lesions also afflicts their joints in a condition called psoriatic arthritis. TNF-alpha has been shown to play a central role in the pathogenesis of both cutaneous and joint disease. Etanercept is a soluble fusion protein that binds TNF-alpha, rendering the molecule inactive and making etanercept an effective, targeted therapeutic option for many TNF-mediated inflammatory diseases. OBJECTIVE: To review the key clinical trials which evaluated efficacy of etanercept for the treatment of psoriasis and psoriatic arthritis, discuss various off-label uses for this therapeutic agent and describe the adverse events associated with its use. METHODS: A search of Medline for relevant articles on etanercept and psoriasis. RESULTS/ CONCLUSION: Etanercept has demonstrated efficacy in the treatment of skin and joint manifestations of psoriatic disease, thus gaining FDA approval for use in both. A growing number of off-label dermatological uses for etanercept have been proposed, with variable success reported in individual cases or small series. Since its introduction little over a decade ago, etanercept has maintained a favorable safety profile.
Authors: Natalia Jaimes-López; Verónica Molina; Juan E Arroyave; Luz A Vasquez; Ana C Ruiz; Rodrigo Castaño; Mario H Ruiz Journal: J Dermatol Case Rep Date: 2009-08-24
Authors: Dirk Brenner; Anne Brüstle; Gloria H Y Lin; Philipp A Lang; Gordon S Duncan; Christiane B Knobbe-Thomsen; Michael St Paul; Colin Reardon; Michael W Tusche; Bryan Snow; Sara R Hamilton; Aline Pfefferle; Syed O Gilani; Pamela S Ohashi; Karl S Lang; Tak W Mak Journal: Proc Natl Acad Sci U S A Date: 2014-01-07 Impact factor: 11.205
Authors: Zhengqiu Zhou; Grant L Austin; Robert Shaffer; Dustin D Armstrong; Matthew S Gentry Journal: Trends Mol Med Date: 2019-09-12 Impact factor: 11.951